Conference Details - Overview
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Eighth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy
New York Marriott Downtown
New York, NY
October 16-18, 2009
Conference Overview
Summary and Purpose
Oncology CME-Certified Congress
The Eighth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy congress will address emerging data that underlie the optimal management of early-stage breast cancer. A significant emphasis on case discussion and available adjuvant and neoadjuvant treatment options will provide a forum to discuss and debate the controversies concerning and practical applicability of evolving clinical trial findings. Other topics pertaining to diagnosis, staging, breast cancer subtypes, risk assessment, toxicity management, and survivorship issues will also be addressed.
The purpose of this congress is to provide an update on the latest advances in the management of early-stage breast cancer, addressing key areas of controversy.
Follow us on Twitter @ControBrCa
www.twitter.com/ControBrCa
Target Audience
This educational program is directed toward medical, surgical, and radiation oncologists practicing in the community or at academic institutions. Fellows, nurses, physician assistants, and pharmacists with an interest in the treatment of breast cancer are also invited to attend.Learning Objectives
At the conclusion of this congress, you should be able to:
- Review new diagnostic and management insights into hereditary breast cancers
- Describe the principles of state-of-the-art imaging and surgical techniques as well as radiation therapy and apply them to the treatment of patients with breast cancer
- Review the latest data on preoperative therapies and surgical and radiation therapy management strategies
- Review and debate the clinical utility and implications of novel genomic and pathologic diagnostic tools to subset breast cancer
- Discuss the utility of algorithms and genomic tools to assess recurrence risk and predict benefit from adjuvant chemotherapy, hormonal therapy, and HER2-targeted therapy for individual patients
- Evaluate novel cytotoxic and biologic agents and their utility in neoadjuvant or adjuvant regimens
- Evaluate data from recent adjuvant chemotherapy clinical trials and use them to optimize and individualize treatment for patients with early-stage breast cancer
- Analyze the efficacy of adjuvant chemotherapy by breast cancer subtype
- Review the latest clinical data on adjuvant endocrine therapy, including up-front versus switching strategies and extended therapy with selective estrogen receptor modulators and aromatase inhibitors
- Apply key data on bisphosphonates from trials assessing outcomes on bone health and recurrence risk to the management of patients in defined clinical scenarios
- Discuss the recent clinical trial data that provide the underpinnings for state-of-the-art adjuvant and neoadjuvant systemic therapy for breast cancer
- Discuss the mechanisms of action of emerging chemotherapeutic, endocrine, and biologic agents; the rationale for and efficacy of novel combination regimens; and their potential place in therapy
- Guide patients to promising clinical trials
Educational Grants
An educational grant for this activity was provided by:
- Genentech BioOncology
- AstraZeneca
- Novartis Oncology
- sanofi-aventis U.S.